Sun Pharma Wins FDA Approval for ILUMYA in Psoriatic Arthritis
MUMBAI, India and PRINCETON, New Jersey, U.S., October 30, 2026 Sun Pharmaceutical Industries Limited (Sun Pharma) has announced that...
IL-23 Inhibitor
Advertisement
Johnson & Johnson Reports TREMFYA Axial PsA Study Data
Spring House, Pennsylvania, September 25, 2026 Johnson & Johnson announced topline results from the Phase 4 STAR study evaluating...
AbbVie Submits SKYRIZI SC Induction Application to EMA
North Chicago, Illinois, United States, Aug. 27, 2026 AbbVie has submitted a regulatory application to the European Medicines Agency...
AbbVie Secures FDA Approval for SKYRIZI in Pediatric Psoriatic Disease
NORTH CHICAGO, Ill., June 26, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI®...
Immunic Presents New Phase 2 Data Supporting Vidofludimus Calcium in Progressive MS
NEW YORK, May 28, 2026 Immunic, Inc. has unveiled new analyses from its Phase 2 CALLIPER trial evaluating vidofludimus...
Advertisements
Johnson & Johnson Wins FDA Label Expansion for TREMFYA
HORSHAM, Pennsylvania, May 28, 2026 Johnson & Johnson has secured a major regulatory milestone after the U.S. Food and...
Lilly Omvoh Shows 4-Year UC Disease Clearance Results
INDIANAPOLIS, May 5, 2026 Eli Lilly and Company has reported new long-term clinical data demonstrating that Omvoh® (mirikizumab-mrkz) achieved...
FDA Approves J&J’s ICOTYDE Oral Peptide for Psoriasis
SPRING HOUSE, Pennsylvania, USA – March 18, 2026 In a major advancement for dermatology and systemic therapies, Johnson &...
TREMFYA Sustains UC Remission Through 3 Years
STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study...
Canada Issues Positive Reimbursement Recommendation for Skyrizi in Ulcerative Colitis
Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has...
Advertisement
